A number of regimens are now available that can induce antitumor responses in many patients with non-small cell lung cancer. Surgery remains the treatment of choice in stages I and II. Combination regimens have been demonstrated to elicit higher response rates, as well as an improvement in survival, than single agents or treatment other than chemotherapy for patients with nonresectable tumors. The majority of effective regimens with reproducible activity have used cisplatin as part of the combination. Interesting new agents are now being used in clinical studies, such as monoclonal antibodies, anthracyclines and antifolates, eg, 10-ethyl-deaza-aminopterin.
|Original language||English (US)|
|Number of pages||6|
|Journal||Seminars in oncology|
|Issue number||4 SUPPL. 7|
|Publication status||Published - Jan 1 1990|
ASJC Scopus subject areas